WO1998039464A3 - Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same - Google Patents
Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same Download PDFInfo
- Publication number
- WO1998039464A3 WO1998039464A3 PCT/US1998/004080 US9804080W WO9839464A3 WO 1998039464 A3 WO1998039464 A3 WO 1998039464A3 US 9804080 W US9804080 W US 9804080W WO 9839464 A3 WO9839464 A3 WO 9839464A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- adenoviral
- adenovirus vectors
- methods
- heterologous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53867498A JP2002514074A (en) | 1997-03-03 | 1998-03-03 | Adenovirus vectors containing heterologous transcriptional regulatory elements and methods of using the same |
CA002283231A CA2283231C (en) | 1997-03-03 | 1998-03-03 | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
EP98907702A EP1007715A2 (en) | 1997-03-03 | 1998-03-03 | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
AU63450/98A AU744725B2 (en) | 1997-03-03 | 1998-03-03 | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3976397P | 1997-03-03 | 1997-03-03 | |
US3976297P | 1997-03-03 | 1997-03-03 | |
US60/039,763 | 1997-03-03 | ||
US60/039,762 | 1997-03-03 | ||
US5452397P | 1997-08-04 | 1997-08-04 | |
US60/054,523 | 1997-08-04 | ||
US09/033,556 | 1998-03-02 | ||
US09/033,556 US6432700B1 (en) | 1997-03-03 | 1998-03-02 | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
Publications (4)
Publication Number | Publication Date |
---|---|
WO1998039464A2 WO1998039464A2 (en) | 1998-09-11 |
WO1998039464A3 true WO1998039464A3 (en) | 1999-01-07 |
WO1998039464A9 WO1998039464A9 (en) | 1999-02-18 |
WO1998039464A8 WO1998039464A8 (en) | 1999-04-01 |
Family
ID=27488125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/004080 WO1998039464A2 (en) | 1997-03-03 | 1998-03-03 | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1007715A2 (en) |
JP (1) | JP2002514074A (en) |
AU (1) | AU744725B2 (en) |
CA (1) | CA2283231C (en) |
WO (1) | WO1998039464A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999006576A1 (en) * | 1997-08-04 | 1999-02-11 | Calydon, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
AU4070499A (en) | 1998-04-30 | 1999-11-16 | Cornell Research Foundation Inc. | Adenoviral vectors with tandem fiber proteins |
US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
AU767975B2 (en) | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
US6406861B1 (en) | 1998-10-07 | 2002-06-18 | Cell Genesys, Inc. | Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration |
US6649158B1 (en) | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
CA2345900A1 (en) * | 1998-10-15 | 2000-04-20 | Canji, Inc. | Selectively replicating viral vectors |
US7691370B2 (en) | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
AU6497799A (en) * | 1998-10-15 | 2000-05-01 | Canji, Inc. | Methods and compositions to induce antitumor response |
US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
GB9906815D0 (en) * | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
AU2001247648B2 (en) * | 2000-03-24 | 2006-03-30 | Cold Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
US7048920B2 (en) | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
AU2001243704B2 (en) * | 2000-03-24 | 2005-10-27 | Cell Genesys, Inc. | Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation |
US6911200B2 (en) | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
US6673614B2 (en) | 2000-06-27 | 2004-01-06 | Cell Genesys, Inc. | Rapid methods and kits for detection and semi-quantitation of anti-adenovirus antibody |
JP2004536553A (en) * | 2000-09-30 | 2004-12-09 | ディヴァーサ コーポレイション | Whole-cell engineering by essentially partial mutation of the primordial genome, combination of mutations, and arbitrary repetition |
WO2002068627A2 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constucts |
GB0117198D0 (en) * | 2001-07-13 | 2001-09-05 | Btg Int Ltd | Anti-neoplastic viral agents |
AU2003287451A1 (en) | 2002-11-01 | 2004-06-07 | Cell Genesys, Inc. | Cell-specific adenovirus vector comprising ebv-specific promoter |
EP1597354A4 (en) * | 2003-02-24 | 2008-07-02 | Cell Genesys Inc | System for external control of oncolytic virus replication |
US7482156B2 (en) | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
WO2011043719A1 (en) * | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
JP7208492B2 (en) | 2016-03-10 | 2023-01-19 | シージー オンコロジー, インコーポレイテッド | Methods of treating solid tumors or lymphoid tumors with combination therapy |
AU2018251987A1 (en) | 2017-04-14 | 2019-12-05 | Cg Oncology, Inc. | Methods of treating bladder cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003594A1 (en) * | 1992-08-07 | 1994-02-17 | University Of Manitoba | Androgen regulation with dna sequences of rat probasin gene |
WO1995014100A2 (en) * | 1993-11-19 | 1995-05-26 | The Wellcome Foundation Limited | Transcriptional regulatory sequence of carcinoembryonic antigen for expression targeting |
WO1996017053A1 (en) * | 1994-11-28 | 1996-06-06 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
WO1996034969A2 (en) * | 1995-05-03 | 1996-11-07 | Canji, Inc. | Gene therapy using replication competent targeted adenoviral vectors |
WO1997001358A1 (en) * | 1995-06-27 | 1997-01-16 | Calydon | Tissue specific viral vectors |
-
1998
- 1998-03-03 EP EP98907702A patent/EP1007715A2/en not_active Ceased
- 1998-03-03 WO PCT/US1998/004080 patent/WO1998039464A2/en not_active Application Discontinuation
- 1998-03-03 JP JP53867498A patent/JP2002514074A/en not_active Ceased
- 1998-03-03 AU AU63450/98A patent/AU744725B2/en not_active Expired
- 1998-03-03 CA CA002283231A patent/CA2283231C/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003594A1 (en) * | 1992-08-07 | 1994-02-17 | University Of Manitoba | Androgen regulation with dna sequences of rat probasin gene |
WO1995014100A2 (en) * | 1993-11-19 | 1995-05-26 | The Wellcome Foundation Limited | Transcriptional regulatory sequence of carcinoembryonic antigen for expression targeting |
WO1996017053A1 (en) * | 1994-11-28 | 1996-06-06 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
WO1996034969A2 (en) * | 1995-05-03 | 1996-11-07 | Canji, Inc. | Gene therapy using replication competent targeted adenoviral vectors |
WO1997001358A1 (en) * | 1995-06-27 | 1997-01-16 | Calydon | Tissue specific viral vectors |
Non-Patent Citations (5)
Also Published As
Publication number | Publication date |
---|---|
CA2283231C (en) | 2008-05-20 |
WO1998039464A8 (en) | 1999-04-01 |
AU744725B2 (en) | 2002-02-28 |
AU6345098A (en) | 1998-09-22 |
JP2002514074A (en) | 2002-05-14 |
EP1007715A2 (en) | 2000-06-14 |
WO1998039464A2 (en) | 1998-09-11 |
CA2283231A1 (en) | 1998-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998039464A3 (en) | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same | |
WO2000034496A3 (en) | Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene | |
Sandig et al. | Optimization of the helper-dependent adenovirus system for production and potency in vivo | |
DE69634752D1 (en) | ADENOVIRAL VECTORS CONTAINING A PROSTATE SPECIFIC ANTIGEN (PSA) "RESPONSE ELEMENT" | |
WO2000039319A3 (en) | Target cell-specific adenoviral vectors containing e3 and methods of use thereof | |
ES2151310T3 (en) | NEW CELLULAR COMPLEMENTATION LINES FOR DEFECTIVE ADENOVIRAL VECTORS. | |
WO1997021826A3 (en) | Complementary adenoviral vector systems and cell lines | |
MX9709549A (en) | Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses. | |
DK0695360T3 (en) | Defective recombinant adenoviruses for gene therapy of tumors | |
WO2005001103A3 (en) | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses | |
AU3625997A (en) | Chimeric gene containing several herbicide tolerance genes, plant cell and plant which are tolerant to several herbicides | |
WO1998039467A3 (en) | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof | |
DK136184D0 (en) | PROCEDURE FOR EXPRESSING A GENE CODING PROCHYMOSIN, IN E.COLI HOST CELLS AND EXPRESSION PLASMID USED BY THE PROCEDURE | |
ATE310829T1 (en) | CELL LINES AND CONSTRUCTS FOR PRODUCING E1-DELETED ADENOVIRUSES IN THE ABSENCE OF REPLICATION COMPETENT ADENOVIRUS | |
WO2001036650A3 (en) | An oncolytic adenovirus | |
CA2282812A1 (en) | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof | |
AU5588298A (en) | Adeno-associated viral vector-mediated delivery of dna to cells of the liver | |
EP0999279A4 (en) | Gene transfer method with the use of serum-free medium | |
WO2005052143A3 (en) | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses | |
NZ508399A (en) | Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors | |
WO2001055362A3 (en) | Hybrid adeno-retroviral vector for the transfection of cells | |
WO2001004282A3 (en) | Replication-competent anti-cancer vectors | |
WO2000040741A3 (en) | Lentivirus vector system | |
TR199700535A3 (en) | Floating docks for receiving ships in the pool. | |
WO2000012741A3 (en) | Inducible expression system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/18-18/18, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 36/98 UNDER (30) REPLACE "NOT FURNISHED" BY "09/033556" |
|
ENP | Entry into the national phase |
Ref document number: 2283231 Country of ref document: CA Ref country code: CA Ref document number: 2283231 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998907702 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 63450/98 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998907702 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 63450/98 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1998907702 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998907702 Country of ref document: EP |